

Robert Welte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11584011/publications.pdf>

Version: 2024-02-01

13
papers

725
citations

1039406

9
h-index

1199166

12
g-index

13
all docs

13
docs citations

13
times ranked

738
citing authors

#	ARTICLE	IF	CITATIONS
1	A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries. <i>Pharmacoeconomics</i> , 2004, 22, 857-876.	1.7	219
2	Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison. <i>Tobacco Control</i> , 2006, 15, 464-471.	1.8	121
3	Comparative Model-based Analysis of Screening Programs for Chlamydia trachomatis Infections. <i>American Journal of Epidemiology</i> , 2001, 153, 90-101.	1.6	118
4	Cost-Effectiveness of Screening Programs for Chlamydia trachomatis. <i>Sexually Transmitted Diseases</i> , 2000, 27, 518-529.	0.8	84
5	Costs and Effects of Chlamydial Screening: Dynamic versus Static Modeling. <i>Sexually Transmitted Diseases</i> , 2005, 32, 474-483.	0.8	51
6	The Role of Economic Evaluation in Vaccine Decision Making. <i>Pharmacoeconomics</i> , 2005, 23, 855-874.	1.7	36
7	Prediction of Costs, Effectiveness, and Disease Control of a Population-Based Program Using Home Sampling for Diagnosis of Urogenital Chlamydia trachomatis Infections. <i>Sexually Transmitted Diseases</i> , 2006, 33, 407-415.	0.8	35
8	Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands. <i>Sexually Transmitted Infections</i> , 2015, 91, 423-429.	0.8	25
9	Cost-Effectiveness of Partner Pharmacotherapy in Screening Women for Asymptomatic Infection with Chlamydia Trachomatis. <i>Value in Health</i> , 2001, 4, 266-275.	0.1	20
10	Cost-effectiveness of screening asymptomatic women for Chlamydia trachomatis. <i>European Journal of Health Economics</i> , 2000, 1, 103-110.	0.2	7
11	Cost-effectiveness of screening for genital Chlamydia trachomatis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 145-156.	0.7	6
12	Cost-effectiveness of widespread screening for Chlamydia trachomatis. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1443-1450.	0.9	3
13	Die volkswirtschaftlichen Kosten des Zigarettenrauchens in Deutschland. <i>Public Health Forum</i> , 2007, 15, 22-25.	0.1	0